These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25604826)

  • 1. Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM.
    Biswas NK; Chandra V; Sarkar-Roy N; Das T; Bhattacharya RN; Tripathy LN; Basu SK; Kumar S; Das S; Chatterjee A; Mukherjee A; Basu P; Maitra A; Chattopadhyay A; Basu A; Dhara S
    Sci Rep; 2015 Jan; 5():7915. PubMed ID: 25604826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hedgehog signaling pathway is active in GBM with GLI1 mRNA expression showing a single continuous distribution rather than discrete high/low clusters.
    Chandra V; Das T; Gulati P; Biswas NK; Rote S; Chatterjee U; Ghosh SN; Deb S; Saha SK; Chowdhury AK; Ghosh S; Rudin CM; Mukherjee A; Basu A; Dhara S
    PLoS One; 2015; 10(3):e0116390. PubMed ID: 25775002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
    Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
    Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines.
    Ferruzzi P; Mennillo F; De Rosa A; Giordano C; Rossi M; Benedetti G; Magrini R; Pericot Mohr Gl; Miragliotta V; Magnoni L; Mori E; Thomas R; Tunici P; Bakker A
    Int J Cancer; 2012 Jul; 131(2):E33-44. PubMed ID: 22072503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Sonic hedgehog signaling in cell cycle, oxidative stress, and autophagy of temozolomide resistant glioblastoma.
    Honorato JR; Hauser-Davis RA; Saggioro EM; Correia FV; Sales-Junior SF; Soares LOS; Lima LDR; Moura-Neto V; Lopes GPF; Spohr TCLS
    J Cell Physiol; 2020 Apr; 235(4):3798-3814. PubMed ID: 31613002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
    Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
    Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
    Wang P; Ye JA; Hou CX; Zhou D; Zhan SQ
    Oncol Rep; 2016 Nov; 36(5):2544-2552. PubMed ID: 27633132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential role of Gli proteins in glioblastoma multiforme.
    Santoni M; Burattini L; Nabissi M; Morelli MB; Berardi R; Santoni G; Cascinu S
    Curr Protein Pept Sci; 2013 Mar; 14(2):133-40. PubMed ID: 23544423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
    Wong ST; Zhang XQ; Zhuang JT; Chan HL; Li CH; Leung GK
    Anticancer Res; 2012 Jul; 32(7):2835-41. PubMed ID: 22753745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
    She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Xiang J; Wu M; Li G
    Oncol Rep; 2014 Sep; 32(3):957-64. PubMed ID: 25017996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
    Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
    Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
    DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
    Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
    van Nifterik KA; van den Berg J; Stalpers LJ; Lafleur MV; Leenstra S; Slotman BJ; Hulsebos TJ; Sminia P
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1246-53. PubMed ID: 17967314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
    Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
    Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme.
    Fisher T; Galanti G; Lavie G; Jacob-Hirsch J; Kventsel I; Zeligson S; Winkler R; Simon AJ; Amariglio N; Rechavi G; Toren A
    Cancer J; 2007; 13(5):335-44. PubMed ID: 17921733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
    Hirose Y; Berger MS; Pieper RO
    Cancer Res; 2001 Mar; 61(5):1957-63. PubMed ID: 11280752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.